The Elvinix program starts from a simple premise: clinically established type 1 diabetes may leave behind more recoverable insulin-producing capacity than conventional descriptions of irreversible β-cell loss imply.
The potential to recover functional β-cell mass may persist even in clinically established type 1 diabetes.
The capacity to produce insulin is not entirely lost. Elvinix is working to restore normal insulin secretion.
Stage 3 type 1 diabetes is marked by profound loss of β-cell mass and dependence on exogenous insulin. Even so, endogenous insulin secretion remains detectable in many people with long-duration disease, and insulin-containing cells can persist in the pancreas decades after diagnosis. Elvinix is developing a therapy designed to build on these remaining reserves by increasing endogenous insulin production and protecting recovered β-cell mass from further loss.
β-cell mass declines through Stages 1 to 3 but is not completely lost. The Elvinix therapeutic intervention is designed to act on that remaining capacity, increasing functional β-cell mass while controlling autoimmunity.
Elvinix has generated a preclinical package examining the relationship between β-cell restoration, immune protection and post-treatment persistence. The data have informed the company’s therapeutic design and translational plan*.
* Full results are available to qualified investors and scientific reviewers under confidentiality.
This library brings together a non-exhaustive selection of peer-reviewed publications from across the scientific community that informs Elvinix’s understanding of type 1 diabetes and the scientific rationale for its therapeutic approach.
The publications span more than two decades and include work from multiple research groups. They are not presented as research generated by Elvinix. Some publications were authored or co-authored by individuals who are now Elvinix co-founders or scientific advisors; they are included on the basis of their scientific relevance.
Publications are organized around the scientific questions they address. Study context is identified so that findings from human studies, experimental models and platform research can be interpreted appropriately.
Disease-modifying pharmacological treatments of type 1 diabetes: molecular mechanisms, target checkpoints, and possible combinatorial treatments
Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?)
The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells
Residual insulin production and pancreatic β-cell turnover after 50 years of diabetes: Joslin Medalist Study
Insulitis and β-cell mass in the natural history of type 1 diabetes
Function of isolated pancreatic islets from patients at onset of type 1 diabetes: insulin secretion can be restored after some days in a nondiabetogenic environment in vitro — results from the DiViD study
β cells that resist immunological attack develop during progression of autoimmune diabetes in NOD mice
Liraglutide protects β-cells in novel human islet spheroid models of type 1 diabetes
Gastrin stimulates β-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue
Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet β-cells from pancreatic duct cells and an increase in functional β-cell mass
Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice
Combination therapy with glucagon-like peptide-1 and gastrin induces β-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice
Islets from human donors with higher but not lower hemoglobin A1c levels respond to gastrin treatment in vitro
The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice
The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases β-cell mass without affecting islet number in db/db mice
In-vitro and in-vivo studies supporting the therapeutic potential of ZP3022 in diabetes
Non-exhaustive list of literature, provided for scientific context. Elvinix is a preclinical-stage biopharmaceutical company; its therapeutic candidates are investigational and have not been evaluated or approved by any regulatory authority. Nothing here is medical advice.